Lysosomal dysfunction in Down syndrome and Alzheimer mouse models is caused by v-ATPase inhibition by Tyr(682)-phosphorylated APP CTF
In Phase 2 trials, it was administered as a once-weekly subcutaneous injection
While not yet FDA-approved or available for patient use, this method could represent a future option for patients seeking alternatives to injections
Best protein sources for GLP-1 users Not all protein sources perform equally well in the context of delayed gastric emptying and appetite suppression
This may include letters of medical necessity, additional lab results, or a detailed treatment plan from your provider
(2022), the clinical trial with oral administration of FMT capsules in depressed irritable bowel syndrome (IBS) patients enhanced bacterial alpha diversity and increased the abundance of bacterial communities predominantly Bacteroides immitis and Bacteroides thicketi , as well as an attestation to significant improvement in depressive symptoms